Apogen Technologies

Apogen Technologies was a preclinical-stage biotechnology company focused on developing a novel class of small molecule inhibitors targeting the APOBEC family of enzymes. The company's primary focus was on APOBEC3B, a DNA cytosine deaminase that is a major source of genetic mutations in various cancers, including breast, lung, and bladder cancers. By inhibiting these enzymes, Apogen aimed to prevent the genomic instability that allows tumors to evolve and develop resistance to chemotherapy and targeted treatments. The company's approach was designed to be used in combination with existing therapies to improve long-term patient outcomes by stabilizing the cancer genome. Founded on research from the University of Minnesota, Apogen was a pioneer in the field of 'mutational bypass' drug discovery.